Vertex Pharmaceuticals Incorporated (VRTX) CMO Sells $266,616.42 in Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Jeffrey Chodakewitz sold 1,718 shares of the stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $155.19, for a total transaction of $266,616.42. Following the sale, the chief marketing officer now directly owns 116,142 shares of the company’s stock, valued at approximately $18,024,076.98. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Jeffrey Chodakewitz also recently made the following trade(s):

  • On Monday, October 2nd, Jeffrey Chodakewitz sold 3,437 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $151.64, for a total transaction of $521,186.68.
  • On Wednesday, August 2nd, Jeffrey Chodakewitz sold 1,796 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $154.13, for a total transaction of $276,817.48.
  • On Thursday, August 3rd, Jeffrey Chodakewitz sold 5,390 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $154.17, for a total transaction of $830,976.30.
  • On Friday, July 21st, Jeffrey Chodakewitz sold 46,733 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $160.96, for a total transaction of $7,522,143.68.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at 150.11 on Friday. Vertex Pharmaceuticals Incorporated has a 1-year low of $71.46 and a 1-year high of $167.86. The company has a market capitalization of $37.85 billion, a PE ratio of 144.20 and a beta of 1.73. The firm has a 50-day moving average price of $153.41 and a 200-day moving average price of $138.57.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.49. The business had revenue of $578.20 million for the quarter, compared to analyst estimates of $522.07 million. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. Vertex Pharmaceuticals’s quarterly revenue was up 39.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.16 EPS. Equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post $1.63 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/28/vertex-pharmaceuticals-incorporated-vrtx-cmo-jeffrey-chodakewitz-sells-1718-shares.html.

A number of research firms recently issued reports on VRTX. Piper Jaffray Companies reissued an “overweight” rating and set a $205.00 target price on shares of Vertex Pharmaceuticals in a research report on Thursday. Needham & Company LLC reissued a “buy” rating and set a $195.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday. Royal Bank Of Canada reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Friday. Robert W. Baird reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Friday. Finally, Maxim Group reaffirmed a “buy” rating and issued a $195.00 price objective on shares of Vertex Pharmaceuticals in a research report on Thursday. One research analyst has rated the stock with a sell rating, six have issued a hold rating and twenty-three have assigned a buy rating to the company. Vertex Pharmaceuticals has a consensus rating of “Buy” and an average target price of $169.74.

A number of hedge funds have recently made changes to their positions in VRTX. Northwestern Mutual Wealth Management Co. boosted its stake in Vertex Pharmaceuticals by 15.4% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock valued at $127,000 after buying an additional 132 shares in the last quarter. FNY Partners Fund LP boosted its stake in Vertex Pharmaceuticals by 900.0% in the 2nd quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock valued at $128,000 after buying an additional 900 shares in the last quarter. Dupont Capital Management Corp acquired a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at $186,000. State of Alaska Department of Revenue acquired a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at $197,000. Finally, Tocqueville Asset Management L.P. acquired a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at $203,000. 92.93% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply